First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Cancer Immunology, Immunotherapy · Published 2023-01-01 · Available online 21 Jun 2022 · Journal article · DOI 10.1007/s00262-022-03232-2 · PMID: 35729418 · PMC · Cited by 28 (Crossref)
Authors (20)
Renaud Descourt, Laurent Greillier, Maurice Perol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Radj Gervais, Rémi Veillon, Sabine Vieillot, Florian Guisier, Marie Marcq, Grégoire Justeau, Laurence Bigay-Game, Marie Bernardi, Pierre Fournel, Hélène Doubre, Julian Pinsolle, Karim Amrane, Christos Chouaïd, Chantal Decroisette
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Volume
- 72
- Issue
- 1
- Pages
- 91-99
- Year
- 2023
Citation
Descourt, R., Greillier, L., Perol, M., et al. (2023). First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-022-03232-2
Related articles
- Brain metastases in non-small cell lung cancer: Prevalence, high-risk factors, and overall survival prognosis · Forum of Clinical Oncology · 2025 · Cites or is cited by this article
- Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Future Oncology · 2026 · Cites or is cited by this article
- Bridging the Gap in Lung Cancer: Novel Biomarkers, Metabolic Drivers, and Advanced Therapeutics from Bench to Bedside · Biomedicines · 2026 · Cites or is cited by this article
- HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal
Metrics
- Citations (Crossref)
- 28